Dr Reddy's Laboratories has entered into an exclusive agreement with Takeda Pharmaceutical Company to distribute QDENGA, India's first approved dengue vaccine, in the private market. Subject to regulatory processes, the vaccine is expected to become available in the first half of 2027
India's first dengue vaccine, QDENGA, is set to enter the market in the first half of 2027 under an exclusive partnership between Takeda and Dr Reddy's Laboratories. The agreement will facilitate private-market distribution and awareness ahead of the commercial rollout
India has granted market authorisation to Takeda Biopharmaceuticals’ dengue vaccine QDENGA, making it the country’s first approved vaccine for dengue prevention. The approval by CDSCO follows extensive global and Indian clinical trials confirming its safety and efficacy.
Hyderabad’s AIIMS Bibinagar has emerged as a crucial site for India’s first indigenous dengue vaccine, currently in phase III clinical trials. Led by ICMR and developed in partnership with Panacea Biotec, the single-shot tetravalent vaccine is in its final phase of enrollment.
While development of a dengue vaccine has been perennially in the making, the recent launch of the third phase of clinical trials of dengue vaccine in India by ICMR with Panacea Biotec, has raised hopes over the availability of a dengue vaccine to the general public in the next few years.
